Mirador Therapeutics raised over $400M in early funding rounds to develop precision medicines for immune-related diseases.

Mar 21, 2024•over 1 year ago

Amount Raised

$400 Million

Round Type

series a

San DiegoTherapeuticsBiotechnologyHealth Care

Investors

SanofiOrbi MedArch Venture Partners

Description

Mirador Therapeutics announced the successful completion of a rare, large early-stage fundraise, securing over $400 million to develop precision medicines for immune-related diseases. The funding rounds, including seed funding, were led by venture capital firm ARCH Venture Partners, along with other prominent investors such as healthcare-focused firm OrbiMed and Sanofi's SAN venture capital arm.

Company Information

Company

Mirador Therapeutics

Location

San Diego, California, United States

About

Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA.

Related People

4 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends